Macular Degeneration Clinical Trials 2024

What are the top hospitals conducting macular degeneration research?

Macular degeneration, a leading cause of vision loss, is being tackled head-on by several top hospitals in different locations. In Reno, Sierra Eye Associates is making significant strides with 10 active macular degeneration trials and an impressive 48 completed trials to date. Since their first recorded trial in 2013, they have been dedicated to finding innovative solutions for this condition. Meanwhile, Cumberland Valley Retina Consultants in Hagerstown has been actively involved as well, with nine ongoing trials and a history of 16 previous studies since initiating their first macular degeneration trial in 2012.

Retina Consultants of Texas has also emerged as a key player on the medical landscape when it comes to fighting macular degeneration. Located both in Bellaire and The Woodlands, these institutions collectively conduct seventeen active clinical trials that aim to combat this sight-threatening disease. Their contributions span numerous years of research efforts since their initial ventures into macular degeneration trials: Bellaire began theirs in earnest back in 2015 while The Woodlands joined the fight more recently but not less enthusiastically beginning from only three years ago.

In Boston's Ophthalmic Consultants of Boston,a renowned institution engaging seven currently open clinical tests focusing primarily on combating macular degradation; altogether they have conducted forty-three such investigations already representing them one suitable option worth considering if one seeks treatment for preventing further risks.Their contribution dates quite far back compared to others starting way earlier around1999.

These esteemed hospitals provide hope for those affected by macular degeneration by fostering groundbreaking research and offering potential treatments that can improve patients' quality of life. Through tireless dedication and collaborative efforts across various locations nationwide these institutions strive towards better understanding this complex eye condition while actively developing strategies for its management ultimately aiming at restoring or preserving precious eyesight we all cherish

Which are the best cities for macular degeneration clinical trials?

When it comes to clinical trials for macular degeneration, several cities have emerged as leading hubs of research. Phoenix, Arizona, stands out with 32 active trials investigating treatments like RGX-314, IONIS-FB-LRx, and ADVM-022. Close behind is Austin, Texas, with 29 ongoing studies focusing on IONIS-FB-LRx, RGX-314, and Faricimab. Boston and Philadelphia tie with 25 active trials each that explore various treatment options such as RGX-314 Dose 2 and PEGCETACOPLAN (APL-2). Lastly, Baltimore has made significant contributions to the field with its 24 active trials studying interventions including RGX-314 and JNJ-81201887 High dose. These cities offer individuals affected by macular degeneration access to cutting-edge clinical trials that hold promise for advancements in care.

Which are the top treatments for macular degeneration being explored in clinical trials?

Promising treatments for macular degeneration are currently being explored in clinical trials. One such treatment is ALK-001, which has two active trials and a total of two all-time macular degeneration trials since its listing in 2015. Another contender is RGX-314, with two ongoing trials and four previous macular degeneration studies. Finally, there is RGX-314 Dose 2, which joined the scene in 2020 and already has two active trials alongside its two all-time macular degeneration trials. These innovative therapies offer hope for patients battling this debilitating eye condition.

What are the most recent clinical trials for macular degeneration?

Exciting progress is being made in the field of macular degeneration, with recent clinical trials offering promise for improved treatment options. One noteworthy trial involves NG101 gene therapy, which has progressed to Phase 2 after showing positive outcomes in Phase 1. Additionally, an experimental low-dose treatment has shown potential in early phases of development. Another study evaluated the efficacy of KH631 at its initial dose stage, while CT1812 at a dosage of 200 mg underwent Phase 2 testing. These trials mark significant advancements towards finding effective interventions for individuals suffering from macular degeneration.

What macular degeneration clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of macular degeneration, offering hope for improved treatments. Sandoz's trial on SOK583A1 was completed in May 2022, while Kodiak Sciences Inc concluded their study on KSI-301 in June 2021. In that same month, Maturi, Raj K., M.D., P.C.'s investigation into RBM-007 Injectable Solution also reached completion. These breakthroughs join a host of other notable trials like AsclepiX Therapeutics' AXT107 and EyePoint Pharmaceuticals' EYP-1901, both completed in early 2021. The collective efforts of researchers sponsored by various organizations such as Novartis Pharmaceuticals and Hoffmann-La Roche have paved the way for potential advancements against macular degeneration.